Gupta S, Chowdhury N R, Jagtiani R, Gustin K, Aragona E, Shafritz D A, Chowdhury J R, Burk R D
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461.
Transplantation. 1990 Sep;50(3):472-5.
Hepatocytes from donor transgenic mice that produce an easily assayable circulating marker have been used to develop a novel hepatocyte transplantation system. Isolated G7 HBV transgenic donor hepatocytes secreting HBsAg were transplanted into congeneic or allogeneic mouse recipients. Serum HBsAg was present three days after hepatocyte transplantation in congeneic animals and persisted indefinitely when hepatocytes were transplanted into the spleen. Transplanted hepatocytes within the splenic pulp were identified by morphologic and histochemical analysis. Migration of hepatocytes injected into the spleen to the liver was demonstrated by in situ hybridization using an RNA probe for HBsAg. Transplantation into nonimmunosuppressed allogeneic recipients resulted in disappearance of detectable hepatocytes in the spleen within two weeks. This novel transplantation system should facilitate studies of hepatocyte engraftment and survival, modulation of allograft rejection, and development of hepatocyte-directed gene therapy.
来自产生易于检测的循环标志物的供体转基因小鼠的肝细胞已被用于开发一种新型肝细胞移植系统。将分泌乙肝表面抗原（HBsAg）的分离的G7乙肝病毒（HBV）转基因供体肝细胞移植到同基因或异基因小鼠受体中。在同基因动物中，肝细胞移植后三天血清中出现HBsAg，当肝细胞移植到脾脏中时，HBsAg会无限期持续存在。通过形态学和组织化学分析鉴定脾髓内移植的肝细胞。使用针对HBsAg的RNA探针进行原位杂交证明，注入脾脏的肝细胞向肝脏迁移。移植到未免疫抑制的异基因受体中导致两周内脾脏中可检测到的肝细胞消失。这种新型移植系统应有助于肝细胞植入和存活、同种异体移植排斥调节以及肝细胞定向基因治疗的研究。
